Overview
Background
Dr Brett Hughes graduated from the University of NSW with a Bachelor of Medical Science and Bachelor of Medicine and Surgery in 1997. He completed his postgraduate training in Canberra and Brisbane and was admitted as a Fellow of the Australian College of Physicians as a Specialist Medical Oncologist in 2005.
Dr Hughes is currently a Senior Staff Specialist Medical Oncologist at the RBWH and TPCH. He is also an Associate Professor at the University of Queensland since 2015. As the previous Clinical Director of Oncology (201-2017) and current Cancer Care Services Research lead at TPCH, Dr Hughes has established both an independent TPCH Oncology unit and continuing TPCH’s reputation as a lung cancer research centre of excellence.
Dr Hughes is an active senior member of the Thoracic Oncology Group Australasia (TOGA) and the Trans Tasman Radiation Oncology Group (TROG). He is also heavily involved in many pivotal multicentre trials of cancer therapy at both TPCH and RBWH with his principal research interests in Lung cancer, Head & Neck cancer, Mesothelioma, cutaneous SCC and Thyroid cancer. He has published over 100 peer review papers. Dr Hughes is also involved in undergraduate and post graduate teaching in his fields of research interest.
Availability
- Associate Professor Brett Hughes is:
- Available for supervision
Fields of research
Works
Search Professor Brett Hughes’s works on UQ eSpace
2024
Conference Publication
Defining PD-1/PD-L1 receptor-ligand interactions in the head and neck cancer tumor microenvironment identifies unique ‘immune cell rivers’ of cellular interactions
Sadeghirad, Habib, Naei, Vahid Yaghoubi, Monkman, James, Basu, Subham, Wicher, Agata, Ladwa, Rahul, Hughes, Brett G.M. and Kulasinghe, Arutha (2024). Defining PD-1/PD-L1 receptor-ligand interactions in the head and neck cancer tumor microenvironment identifies unique ‘immune cell rivers’ of cellular interactions. American Association for Cancer Research Annual Meeting 2024, San Diego, CA United States, 5-10 April 2024. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2024-5188
2024
Journal Article
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma
Rischin, Danny, Hughes, Brett G. M., Basset-Séguin, Nicole, Schadendorf, Dirk, Bowyer, Samantha, Trabelsi Messai, Sabiha, Meier, Friedegund, Eigentler, Thomas K, Casado Echarren, Victoria, Stein, Brian, Beylot-Barry, Marie, Dalac, Sophie, Dréno, Brigitte, Migden, Michael R, Hauschild, Axel, Schmults, Chrysalyne D, Lim, Annette M, Yoo, Suk-Young, Paccaly, Anne J, Papachristos, Apostolos, Nguyen, Jenny-Hoa, Okoye, Emmanuel, Seebach, Frank, Booth, Jocelyn, Lowy, Israel, Fury, Matthew G and Guminski, Alexander (2024). High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma. Journal for ImmunoTherapy of Cancer, 12 (3) e008325, 1-8. doi: 10.1136/jitc-2023-008325
2024
Journal Article
Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme
Alexander, Marliese, Rogers, Jennifer, Parakh, Sagun, Mitchell, Paul, Clay, Timothy D., Kao, Steven, Hughes, Brett G. M., Itchins, Malinda, Kong, Benjamin Y., Pavlakis, Nick, Solomon, Benjamin J. and John, Thomas (2024). Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme. Internal Medicine Journal, 54 (7), 1087-1096. doi: 10.1111/imj.16348
2024
Journal Article
Nutrition outcomes and treatment toxicities in patients with head and neck cancer receiving helical intensity-modulated radiotherapy
Blake, Claire, Lai, Rainbow, Brown, Teresa, Pelecanos, Anita, Moroney, Laura, Helios, Jennifer, Smith, David, Hughes, Brett G. M., Kenny, Lizbeth, Chua, Benjamin and Bauer, Judith (2024). Nutrition outcomes and treatment toxicities in patients with head and neck cancer receiving helical intensity-modulated radiotherapy. Journal of Human Nutrition and Dietetics, 37 (1), 182-192. doi: 10.1111/jhn.13243
2024
Journal Article
Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study
McLean, Luke S, Lim, Annette M, Bressel, Mathias, Lee, Jenny, Ladwa, Rahul, Guminski, Alexander D, Hughes, Brett, Bowyer, Samantha, Briscoe, Karen, Harris, Samuel, Kukard, Craig, Zielinski, Rob, Alamgeer, Muhammad, Carlino, Matteo, Mo, Jeremy, Park, John J, Khattak, Muhammad A, Day, Fiona and Rischin, Danny (2024). Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study. Medical Journal of Australia, 220 (2), 80-90. doi: 10.5694/mja2.52199
2023
Journal Article
Health-related quality of life with pembrolizumab in patients with locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma: KEYNOTE-629
Bratland, Åse, Munoz-Couselo, Eva, Mortier, Laurent, Roshdy, Osama, González, Rene, Schachter, Jacob, Arance, Ana M., Grange, Florent, Meyer, Nicolas, Joshi, Abhishek Jagdish, Billan, Salem, Hughes, Brett G. M., Grob, Jean-Jacques, Ramakrishnan, Karthik, Ge, Joy, Gumuscu, Burak, Swaby, Ramona F. and Gutzmer, Ralf (2023). Health-related quality of life with pembrolizumab in patients with locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma: KEYNOTE-629. Dermatology and Therapy, 13 (12), 3165-3180. doi: 10.1007/s13555-023-01059-y
2023
Journal Article
Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study
Gross, Neil D., Miller, David M., Khushalani, Nikhil I., Divi, Vasu, Ruiz, Emily S., Lipson, Evan J., Meier, Friedegund, Su, Yungpo Bernard, Swiecicki, Paul L., Atlas, Jennifer, Geiger, Jessica L., Hauschild, Axel, Choe, Jennifer H., Hughes, Brett G. M., Schadendorf, Dirk, Patel, Vishal A., Homsi, Jade, Taube, Janis M., Lim, Annette M., Ferrarotto, Renata, Yoo, Suk-Young, Mathias, Melissa, Han, Hyunsil, Seebach, Frank, Lowy, Israel, Fury, Matthew G. and Rischin, Danny (2023). Neoadjuvant cemiplimab and surgery for stage II–IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study. The Lancet Oncology, 24 (11), 1196-1205. doi: 10.1016/S1470-2045(23)00459-X
2023
Journal Article
A tailored approach to horizon scanning for cancer medicines
Soon, Jennifer A., To, Yat Hang, Alexander, Marliese, Trapani, Karen, Ascierto, Paolo A., Athan, Sophy, Brown, Michael P., Burge, Matthew, Haydon, Andrew, Hughes, Brett, Itchins, Malinda, John, Thomas, Kao, Steven, Koopman, Miriam, Li, Bob T., Long, Georgina V., Loree, Jonathan M., Markman, Ben, Meniawy, Tarek M., Menzies, Alexander M., Nott, Louise, Pavlakis, Nick, Petrella, Teresa M., Popat, Sanjay, Tie, Jeanne, Xu, Wen, Yip, Desmond, Zalcberg, John, Solomon, Benjamin J. ... IJzerman, Maarten (2023). A tailored approach to horizon scanning for cancer medicines. Journal of Cancer Policy, 38 100441, 1-8. doi: 10.1016/j.jcpo.2023.100441
2023
Journal Article
Development and validation of txSim: A model of advanced lung cancer treatment in Australia
Ngo, Preston, Karikios, Deme, Goldsbury, David, Wade, Stephen, Lwin, Zarnie, Hughes, Brett G. M., Fong, Kwun M., Canfell, Karen and Weber, Marianne (2023). Development and validation of txSim: A model of advanced lung cancer treatment in Australia. PharmacoEconomics, 41 (11), 1525-1537. doi: 10.1007/s40273-023-01291-6
2023
Journal Article
Mapping the spatial proteome of head and neck tumors: key immune mediators and metabolic determinants in the tumor microenvironment
Jhaveri, Niyati, Ben Cheikh, Bassem, Nikulina, Nadezhda, Ma, Ning, Klymyshyn, Dmytro, DeRosa, James, Mihani, Ritu, Pratapa, Aditya, Kassim, Yasmin, Bommakanti, Sidharth, Shang, Olive, Berry, Shannon, Ihley, Nicholas, McLane, Michael, He, Yan, Zheng, Yi, Monkman, James, Cooper, Caroline, O'Byrne, Ken, Anand, Bhaskar, Prater, Michael, Basu, Subham, Hughes, Brett G. M., Kulasinghe, Arutha and Braubach, Oliver (2023). Mapping the spatial proteome of head and neck tumors: key immune mediators and metabolic determinants in the tumor microenvironment. GEN Biotechnology, 2 (5), 418-434. doi: 10.1089/genbio.2023.0029
2023
Conference Publication
Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT)
Dingemans, Anne-Marie C., Syrigos, Konstantinos, Livi, Lorenzo, Paulus, Astrid, Kim, Sang-We, Chen, Yuanbin, Felip, Enriqueta, Griesinger, Frank, Ohashi, Kadoaki, Zalcman, Gerard, Hughes, Brett Gordon Maxwell, Sorensen, Jens Benn, Blais, Normand, Ferreira, Carlos G. M., Lindsay, Colin R, Dziadziuszko, Rafal, Ward, Patrick J., Obiozor, Cynthia Chinedu, Wang, Yang and Peters, Solange (2023). Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT). 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.17_suppl.lba9016
2023
Conference Publication
Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R)
Forde, Patrick M., Nowak, Anna K., Hughes, Brett Gordon Maxwell, Kok, Peey Sei, Brown, Chris, Sun, Zhuoxin, Anagnostou, Valsamo, O'Byrne, Ken, Yip, Sonia, Cook, Alistair, Lesterhuis, Willem Joost, Pavlakis, Nick, Brahmer, Julie R., Kindler, Hedy L., Tsao, Anne S., Zauderer, Marjorie Glass, Ramalingam, Suresh S. and Stockler, Martin R. (2023). Durvalumab with chemotherapy as first line treatment in advanced pleural mesothelioma: A phase 3, randomised trial (DREAM3R). 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.tps8599
2023
Conference Publication
Spatial phenotyping of cytokine signatures reflecting the immunotherapy responses in head and neck cancer
Ji, HaYeun, Jhaveri, Niyati, Pratapa, Aditya, Ma, Ning, Ben Cheikh, Bassem, Monkman, James, O’Byrne, Ken, Hughes, Brett, Kulasinghe, Arutha and Braubach, Oliver (2023). Spatial phenotyping of cytokine signatures reflecting the immunotherapy responses in head and neck cancer. Immunology 2023™ Meeting, Washington, DC United States, 11-15 May 2023. Rockville, MD United States: American Association of Immunologists. doi: 10.4049/jimmunol.210.supp.171.09
2023
Conference Publication
Abstract 4626: Spatial profiling of the tumor microenvironment in head and neck cancer identifies immune checkpoints and proteins involved in cell death signaling biomarkers of immunotherapy response
Sadeghirad, Habib, Liu, Ning, Monkman, James, Tan, Chin Wee, Cooper, Caroline, Caldera, Jeni, Church, Sarah, Schneider, Fabian, Mansfield, James Robert, O'Byrne, Ken, Davis, Melissa, Hughes, Brett and Kulasinghe, Arutha (2023). Abstract 4626: Spatial profiling of the tumor microenvironment in head and neck cancer identifies immune checkpoints and proteins involved in cell death signaling biomarkers of immunotherapy response. AACR Annual Meeting 2023, Orlando, FL United States, 14-19 April 2023. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2023-4626
2023
Conference Publication
Abstract 5647: Single cell, multiomic spatial phenotyping of immunotherapy responses in head and neck cancer
Ji, HaYeun, Jhaveri, Niyati, Ma, Ning, Cheikh, Bassem B., Pratapa, Aditya, Monkman, James, O’Byrne, Ken, Hughes, Brett, Kulasinghe, Arutha and Braubach, Oliver (2023). Abstract 5647: Single cell, multiomic spatial phenotyping of immunotherapy responses in head and neck cancer. AACR Annual Meeting 2023, Orlando, FL United States, 14-19 April 2023. Philadelphia, PA United States: American Association for Cancer Research. doi: 10.1158/1538-7445.am2023-5647
2023
Journal Article
Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy
Sadeghirad, Habib, Liu, Ning, Monkman, James, Ma, Ning, Cheikh, Bassem Ben, Jhaveri, Niyati, Tan, Chin Wee, Warkiani, Majid Ebrahimi, Adams, Mark N., Nguyen, Quan, Ladwa, Rahul, Braubach, Oliver, O’Byrne, Ken, Davis, Melissa, Hughes, Brett G. M. and Kulasinghe, Arutha (2023). Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy. Frontiers in Immunology, 14 1135489, 1-16. doi: 10.3389/fimmu.2023.1135489
2023
Journal Article
LOREALAUS: LOrlatinib REAL world AUStralian experience in advanced ALK rearranged non-small cell lung cancer
Alexander, Marliese, Wei, Joe, Parakh, Sagun, John, Thomas, Kao, Steven, Nagrial, Adnan, Bowyer, Samantha, Warburton, Lydia, Moore, Melissa, Hughes, Brett G. M., Clay, Timothy D., Pavlakis, Nick, Solomon, Benjamin J. and Itchins, Malinda (2023). LOREALAUS: LOrlatinib REAL world AUStralian experience in advanced ALK rearranged non-small cell lung cancer. JTO Clinical and Research Reports, 4 (4) 100490, 1-13. doi: 10.1016/j.jtocrr.2023.100490
2023
Journal Article
Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day
Taylor, Matthew H., Leboulleux, Sophie, Panaseykin, Yury, Konda, Bhavana, de La Fouchardiere, Christelle, Hughes, Brett G. M., Gianoukakis, Andrew G., Park, Young Joo, Romanov, Ilia, Krzyzanowska, Monika K., Garbinsky, Diana, Sherif, Bintu, Pan, Jie Janice, Binder, Terri A., Sauter, Nicholas, Xie, Ran and Brose, Marcia S. (2023). Health‐related quality‐of‐life analyses from a multicenter, randomized, double‐blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day. Cancer Medicine, 12 (4), 4332-4342. doi: 10.1002/cam4.5308
2023
Journal Article
Enteral nutrition support and treatment toxicities in patients with head and neck cancer receiving definitive or adjuvant helical intensity‐modulated radiotherapy with concurrent chemotherapy
Blake, Claire L., Brown, Teresa E., Pelecanos, Anita, Moroney, Laura B., Helios, Jennifer, Hughes, Brett G. M., Chua, Benjamin and Kenny, Lizbeth M. (2023). Enteral nutrition support and treatment toxicities in patients with head and neck cancer receiving definitive or adjuvant helical intensity‐modulated radiotherapy with concurrent chemotherapy. Head and Neck, 45 (2), 417-430. doi: 10.1002/hed.27249
2022
Journal Article
Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer
Miller, Richard A., Luke, Jason John, Hu, Shenshen, Mahabhashyam, Suresh, Jones, William B., Marron, Thomas, Merchan, Jaime R., Hughes, Brett G. M. and Willingham, Stephen B. (2022). Anti-CD73 antibody activates human B cells, enhances humoral responses and induces redistribution of B cells in patients with cancer. Journal for ImmunoTherapy of Cancer, 10 (12) e005802, e005802. doi: 10.1136/jitc-2022-005802
Supervision
Availability
- Associate Professor Brett Hughes is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Developing predictive biomarkers for immunotherapy using deep spatial profiling
Associate Advisor
Other advisors: Associate Professor Arutha Kulasinghe
-
Doctor Philosophy
The changing face of head and neck cancer: addressing and advancing best-practice nutritional care to improve outcomes for patients with human papillomavirus-associated disease
Associate Advisor
Completed supervision
-
2025
Doctor Philosophy
The investigation of the tumour microenvironment in head and neck squamous cell carcinoma to identify predictive biomarkers of response to immunotherapy
Associate Advisor
Other advisors: Dr Quan Nguyen, Associate Professor Arutha Kulasinghe
Media
Enquiries
For media enquiries about Associate Professor Brett Hughes's areas of expertise, story ideas and help finding experts, contact our Media team: